首页> 美国卫生研究院文献>Journal of Aerosol Medicine and Pulmonary Drug Delivery >Homogeneity of Aerosol Deposition and Mucociliary Clearance are Improved Following Ivacaftor Treatment in Cystic Fibrosis
【2h】

Homogeneity of Aerosol Deposition and Mucociliary Clearance are Improved Following Ivacaftor Treatment in Cystic Fibrosis

机译:囊泡性纤维化中的依伐卡托治疗后气溶胶沉积和粘膜纤毛清除的同质性得到改善

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

>Background: Using planar gamma scintigraphy of inhaled radioaerosols, we have developed new analytical methods for assessing homogeneity of aerosol deposition and time-dependent particle clearance on a pixel-by-pixel basis, and applied them to a therapeutic cystic fibrosis (CF) study.>Methods: At baseline and 1 month after beginning treatment with ivacaftor, a cystic fibrosis transmembrane regulator modulator for CF patients with at least one copy of the G551D mutation (n = 13), initial deposition and subsequent mucociliary clearance (MCC) of radiolabeled particles (99mTechnetium-sulfur colloid, 5 μm mass median aerodynamic diameter) inhaled under controlled breathing conditions were measured.>Results: Improved homogeneity of deposition, that is, decreased areas of higher and lower particle deposition in the lungs, was observed following ivacaftor treatment. The mean number ratio (NR) of pixels with higher deposition, relative to lung size, decreased from 0.14 to 0.09 (p = 0.003) and mean NR of colder pixels decreased from 0.23 to 0.19 (p = 0.004). Particle clearance was also improved following treatment, with mean MCC through 60 minutes equal to 12% versus 24%, without and with treatment, respectively (p = 0.010). Pixel-level analysis of MCC showed that (1) the fraction of pixels clearing >30% at 60 minutes was increased from 0.13 to 0.32 (p = 0.007); and (2) the fraction of pixels clearing <5% at 60 minutes was decreased from 0.54 to 0.37 (p = 0.014), indicating an overall recruitment of more fast-clearing lung regions with ivacaftor treatment.>Conclusion: These detailed pixel analyses of deposition and clearance homogeneity may supplement traditional methods that use large regions of interest for assessing efficacy and mechanisms of therapeutic intervention in patients with airways disease.
机译:>背景:我们使用吸入式放射气溶胶的平面伽玛闪烁显像技术,开发了一种新的分析方法,用于逐个像素地评估气溶胶沉积的均匀性和时间依赖性颗粒清除率,并将其应用于治疗>方法:在基线期和开始使用依伐卡托治疗后1个月,一种囊性纤维化跨膜调节剂调节剂可用于CF患者,至少具有一份G551D突变(n = 13)。 ,在受控呼吸条件下吸入的放射性标记颗粒( 99m Tech硫胶体,5μm质量平均空气动力学直径)的初始沉积和随后的粘膜纤毛清除率(MCC)进行了测量。>结果:依伐卡托治疗后,观察到改善的沉积均匀性,即减少了肺中较高和较低的颗粒沉积面积。相对于肺尺寸,具有较高沉积的像素的平均数比(NR)从0.14降低至0.09(p = 0.003),而较冷像素的平均NR从0.23降低至0.19(p = 0.004)。处理后的颗粒清除率也得到了改善,在60分钟内的平均MCC分别等于未经处理和经过处理的12%与24%(p = 0.010)。 MCC的像素级分析显示:(1)在60分钟时像素清除率> 30%的比例从0.13增加到0.32(p = 0.007); (2)60分钟时像素清除率低于5%的比例从0.54降低至0.37(p = 0.014),表明采用依伐卡托治疗后,肺部较快清除区域的整体募集。>结论:这些沉积物和清除物均匀性的详细像素分析可以补充传统方法,这些方法使用大面积的目标区域来评估气道疾病患者的疗效和治疗干预机制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号